This inventor holds 4 USPTO granted patents and 5 published patent applications and 4 EPO patents. Top assignees: Minoryx Therapeutics S.l., Institucio Catalana De Recerca I Estudis Avancats, Universität De Barcelona. Active years: 2021-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Barcelona, ES (2021 - 2022)
- Montferri, ES (2023)
Company Filing History:
3 out of 10 
1 out of 93 
1 out of 56 
Years Active: 2021-2025
Title: Innovations of Xavier Barril Alonso
Introduction
Xavier Barril Alonso is a notable inventor based in Barcelona, Spain. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific cellular processes. With a total of four patents to his name, his work has implications for treating various diseases.
Latest Patents
One of his latest patents focuses on inhibitors of ERK nuclear translocation. This patent describes compounds having specific formulas that can inhibit the nuclear translocation of ERK1/2 in cells. The compounds may also be utilized in treating diseases associated with this process. Another significant patent involves heteroaryl compounds, which are directed towards treating lysosomal storage diseases, such as Gaucher's disease, and other disorders related to synucleinopathies.
Career Highlights
Throughout his career, Xavier has worked with several prominent companies, including Minoryx Therapeutics and Yeda Research and Development Company. His expertise in pharmaceutical development has positioned him as a key figure in his field.
Collaborations
Xavier has collaborated with notable colleagues, including Ana Maria García Collazo and Elena Cubero Jordà. These partnerships have contributed to the advancement of his research and innovations.
Conclusion
Xavier Barril Alonso's work exemplifies the impact of innovative thinking in the pharmaceutical industry. His patents and collaborations highlight his commitment to addressing complex medical challenges through scientific research.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile